10-Q Impact 7/10 Earnings

$CFG · CITIZENS FINANCIAL GROUP INC/RI

October 28, 2026 · AI-analyzed SEC filing

Citizens Financial Group filed its Q3 2026 10-Q, reporting net income of $636M ($1.41 diluted EPS) on revenue of $2.322B, up 9.6% YoY. Net interest margin expanded 19 bps to 3.18%, while the provision for credit losses fell to $125M from $154M. Total assets reached $234.5B with deposits of $185.2B and stockholders' equity of $25.2B.

  • Net income of $636M, up 29% YoY from $494M; diluted EPS of $1.41 vs. $1.05 in Q3 2025.
  • Revenue of $2.322B, up 9.6% YoY, driven by net interest income growth of $187M to $1.675B.
  • Net interest margin expanded 19 bps YoY to 3.18%, benefiting from lower terminated swap impacts and improved funding costs.
  • Provision for credit losses declined to $125M from $154M YoY, reflecting improving credit conditions.
  • Issued $400M of 6.75% Series J Preferred Stock in July 2026; net proceeds of $395M.
PeriodQ3 FY2026
ResultBeat
Revenue$2.322B
Revenue YoY+9.6%
EPS$1.41
Net income$636M

Extended-hours trading shows CFG at $65.50, up 0.35% from the regular-session close of $65.27, suggesting a modestly positive initial reception to the strong earnings beat and NIM expansion.

A 29% net income surge with simultaneous NIM expansion and declining credit provisions signals a regional bank hitting an inflection point in the rate cycle.

CFG's 19 bps NIM expansion and 9.6% revenue growth outpace many regional bank peers still struggling with deposit cost pressures, positioning it as a relative winner in the current rate environment.

Forward-looking statements highlight risks from interest rate environment, tariffs, inflationary pressures, and geopolitical instability (Ukraine, Middle East) that could adversely affect credit quality and NIM. CRE exposure remains a watchpoint given the loan portfolio composition.

Get filings like this before the market reacts.

Real-time SEC filing alerts, AI summaries, and a free daily digest — plus portfolio tracking that ties filings to your positions.

Start your free trial →